AVXL ANAVEX LIFE SCIENCES CORP.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1314052 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY73.0%
TTM EPS YoY75.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-12.8%
ROA-11.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.25x
Accruals ratio14.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $37.59M | $41.84M |
| SG&A expense | $13.82M | $11.04M |
| Operating income | -$51.41M | -$52.88M |
| Pretax income | -$46.38M | -$43.00M |
| Net income | -$46.38M | -$43.00M |
| EPS (basic) | -0.54 | -0.52 |
| EPS (diluted) | -0.54 | -0.52 |
| Weighted avg. shares (diluted) | 85.29M | 83.47M |
| Banking | ||
| Net interest income | $4.68M | $7.32M |
| Balance sheet | ||
| Cash & equivalents | $102.58M | $132.19M |
| Total assets | $103.81M | $135.57M |
| Total liabilities | $8.95M | $15.30M |
| Shareholders' equity | $94.87M | $120.26M |
| Shares outstanding | 86.67M | 84.80M |
| Cash flow statement | ||
| Operating cash flow | -$39.04M | -$30.81M |
| Financing cash flow | $9.43M | $11.97M |
| Stock-based compensation | $11.55M | $9.44M |
Free plan shows the latest 2 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.